Evidence map›Paper›PMID 29187403›Full record

ArticleCancer research2018

Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery.

Huang-Chiao Huang, Imran Rizvi, Joyce Liu, Sriram Anbil, Ashish Kalra, Helen Lee, Yan Baglo, Nancy Paz, Douglas Hayden, Steve Pereira and 3 more

Abstract read
In one paragraph

Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Huang-Chiao Huang *Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Imran Rizvi *Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Joyce Liu *Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Sriram AnbilWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Ashish KalraMerrimack Pharmaceuticals, Inc., Cambridge, Massachusetts.
Helen LeeMerrimack Pharmaceuticals, Inc., Cambridge, Massachusetts.
Yan BagloWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Nancy PazMerrimack Pharmaceuticals, Inc., Cambridge, Massachusetts.
Douglas HaydenMGH Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts.
Steve PereiraUCL Institute for Liver and Digestive Health, University College London, London, United Kingdom.
Brian W PogueThayer School of Engineering, Dartmouth College, Hanover, New Hampshire.
Jonathan FitzgeraldMerrimack Pharmaceuticals, Inc., Cambridge, Massachusetts.
Tayyaba HasanWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. thasan@mgh.harvard.edu.

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Bryan Quilty Spring · 2001 to 2026
$27.9M
Targeted Photoactivable Nanocells: Image-based Drug Delivery and Dosimetry in GBMR01CA156177 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA, POGUE, BRIAN WILLIAM · 2011 to 2015
$2.5M
Ovarian Cancer PDT: Multi-intracellular targeting and Image-guided dosimetryR01CA160998 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2011 to 2015
$2.0M
Targeting Determinants of OvCa Metastases in Engineered 3D Microfluidic PlatformsR00CA175292 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RIZVI, IMRAN · 2016 to 2019
$746k
Multifunctional, GBM-Activatable Nanocarriers For Image-Guided PhotochemotherapyR00CA194269 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HUANG, HUANG CHIAO · 2018 to 2020
$701k
Multifunctional, GBM-activatable nanocarriers for image-guided photochemotherapyK99CA194269 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HUANG, HUANG CHIAO · 2016 to 2017
$358k
Targeting Determinants of OvCa Metastases in Engineered 3D Microfluidic PlatformsK99CA175292 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI RIZVI, IMRAN · 2014 to 2015
$350k
Department of Health PB-PG-0712-28114Howard Hughes Medical InstituteMedical Research Council G0801588NCATS NIH HHS UL1 TR001102NCI NIH HHS K99 CA175292NCI NIH HHS K99 CA194269NCI NIH HHS P01 CA084203NCI NIH HHS R00 CA175292NCI NIH HHS R00 CA194269NCI NIH HHS R01 CA156177NCI NIH HHS R01 CA160998
6 · The paper itself

Abstract

Physiologic barriers to drug delivery and selection for drug resistance limit survival outcomes in cancer patients. In this study, we present preclinical evidence that a subtumoricidal photodynamic priming (PDP) strategy can relieve drug delivery barriers in the tumor microenvironment to safely widen the therapeutic window of a nanoformulated cytotoxic drug. In orthotopic xenograft models of pancreatic cancer, combining PDP with nanoliposomal irinotecan (nal-IRI) prevented tumor relapse, reduced metastasis, and increased both progression-free survival and 1-year disease-free survival. PDP enabled these durable improvements by targeting multiple tumor compartments to (i) increase intratumoral drug accumulation by >10-fold, (ii) increase the duration of drug exposure above a critical therapeutic threshold, and (iii) attenuate surges in CD44 and CXCR4 expression, which mediate chemoresistance often observed after multicycle chemotherapy. Overall, our results offer preclinical proof of concept for the effectiveness of PDP to minimize risks of tumor relapse, progression, and drug resistance and to extend patient survival.

Indexed as

Drug Delivery SystemsPhotochemotherapyAnimalsAntineoplastic AgentsApoptosisBiomarkers, TumorCamptothecinCell ProliferationHumansIrinotecanLiposomesMaleMiceMice, NudeNanoparticlesPancreatic NeoplasmsAntineoplastic AgentsBiomarkers, TumorCamptothecinCXCR4 protein, humanIrinotecanLiposomesReceptors, CXCR4

Identifiers

PMID29187403
PMCPMC5771811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.